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Aquaporin 5-deficient mouse lungs are hyperresponsive to cholinergic stimulation
Carissa M. Krane, Christopher N. Fortner, [...], and Anil G. Menon

ABSTRACT
Although aquaporin 5 (AQP5) is the major water channel expressed in alveolar type I cells in the lung, its actual role in the lung is a
matter of considerable speculation. By using immunohistochemical staining, we show that AQP5 expression in mouse lung is not restricted
to type I cells, but is also detected in alveolar type II cells, and in tracheal and bronchial epithelium. Aqp5 knockout (Aqp5−/− ) mice were
used to analyze AQP5 function in pulmonary physiology. Compared with Aqp5+/+ mice, Aqp5−/− mice show a significantly increased
concentrationdependent bronchoconstriction to intravenously administered Ach, as shown by an increase in total lung resistance and a
decrease in dynamic lung compliance (P < 0.05). Likewise, Penh, a measure of bronchoconstriction, was significantly enhanced in Aqp5−/
−

mice challenged with aerosolized methacholine (P < 0.05). The hyperreactivity to bronchoconstriction observed in the Aqp5−/− mice

was not due to differences in tracheal smooth muscle contractility in isolated preparations or to altered levels of surfactant protein B.
These data suggest a novel pathway by which AQP5 influences bronchoconstriction. This observation is of special interest because studies
to identify genetic loci involved in airway hyperresponsiveness associated with asthma bracket genetic intervals on human chromosome
12q and mouse chromosome 15, which contain the Aqp5 gene.
Aquaporin 5 (AQP5) is a mercurysensitive water channel expressed in mouse salivary gland acinar cells, alveolar type I cells, lacrimal
glands, and the eye (1–3). However, the function of AQP5 in mouse lung physiology and pathophysiology is largely unknown. Recent
studies have explored the regulation of Aqp5 gene expression in normal and disease states. In a mouse model of acute lung injury, AQP5
mRNA and protein expression were significantly decreased in association with pulmonary inflammation and edema resulting from
adenoviral infection (4). Moreover, AQP5 expression in a murine lung epithelial cell line (MLE12) is modulated by the proinflammatory
cytokine TNFα through an nuclear factor (NF)κBdependent pathway (5). Keratinocyte growth factor also has been shown to mediate
the differentiation status of alveolar epithelial cells and AQP5 expression (6). However, a clear understanding of AQP5 function in the
lung remains to be discerned.
Previously published studies have addressed functional questions limited to the examination of the role of AQP5 in type I cells in fluid
clearance and airspacecapillary osmotic water permeability. Of significance, isolated perfused lungs from Aqp5−/− mice were shown to
have a 10fold reduction in airspacecapillary osmotic water permeability (7). Experiments addressing the role of AQP5 in alveolar fluid
clearance failed to indicate a role for AQP5 in this process under certain physiological conditions (8). Based on the results of these
studies, some have concluded that AQP5 does not play a major role in lung physiology. Contrary to these conclusions, the data reported
here clearly define a novel function for AQP5 in lung physiology.
In this report, we have examined the expression pattern of AQP5 in the lung and have shown that, in addition to expression in alveolar
type I cells, AQP5 is also detected in alveolar type II cells and tracheal and bronchial epithelium in mice. By using Aqp5−/− mice, we
have directly assessed AQP5 function in the lung by using histological and physiological analyses. Our results show a novel role for AQP5
in airway responsiveness. Interestingly, previously reported genetic linkage studies identify syntenic regions of mouse chromosome 15 (9)
and human chromosome 12q (10, 11), in which Aqp5 resides (12, 13), as containing loci linked with hyperreactivity to
bronchoconstriction. This genetic evidence supports the physiological results presented here, which implicate AQP5 in the pathogenesis of
bronchial hyperreactivity.

METHODS
Aqp5-Deficient Mice. Mice null for Aqp5 were generated as described (14). Mice were bred and housed in a pathogenfree environment.
Age and sexmatched 12weekold Aqp5+/+ and Aqp5−/− littermates (F4 generation) from Aqp5 recombinant inbred 129SvJ/Black Swiss
(line 187) were used in all experiments. All experiments involving the use of live mice were approved by the Institutional Animal Care
and Use Committee review board of the University of Cincinnati College of Medicine.
Histology and Immunohistochemistry. Mouse lungs from 12weekold sexmatched Aqp5+/+ and Aqp5−/− littermates were inflationfixed in
phosphate buffered 4% paraformaldehyde, paraffinembedded, and sectioned at 5 μm. Immunohistochemical staining was evaluated as
described (4), by using a peptidederived, monospecific rabbit polyclonal antibody raised against the mouse/rat AQP5 Cterminal peptide

sequence (LL639; 0.5 μg/ml; ref. 13) and a Vectastain ABC Peroxidase Elite AntiRabbit IgG kit (Vector Laboratories, Burlingame, CA)
to detect the antigen:antibody complexes. Briefly, inflationfixed lungs were washed in PBS and paraffin embedded. Paraffinembedded
lungs were section at 5 μm and deparaffinized in HemoDe (Fisher Scientific), followed by ethanol rehydration. Slides were placed in
methanol containing 0.5% hydrogen peroxide for the removal of endogenous peroxidase activity. Nonspecific binding was blocked by
incubation of the sections in 0.1 M PBS (pH 7.4), containing 0.2% Triton X100 and 2% normal goat serum at room temperature for 1 h.
Lung sections were incubated with peptidederived polyclonal antibody raised against mouse/rat AQP5 Cterminal peptide residues
(LL639; 0.5 μg/ml; ref. 13) overnight at 4°C. Sections were rinsed five times in 0.1 M PBS0.2% Triton X100 and incubated for 1 h at
room temperature with biotinylated goat antirabbit secondary antibody (Vector Laboratories), followed by incubation with an avidin
biotin complex (Vector Laboratories) for 1 h at room temperature. Sections were washed with PBS, rinsed in 0.1 M acetate buffer (pH
6.0), and incubated with NiDAB in 0.1 M acetate buffer (pH 6.0) for 4 min, rinsed, in Tris Buffer (pH 7.6) and incubated in Triscobalt
for 4 min, rinsed, and counterstained with Nuclear Fast Red (Vector Laboratories). Labeling controls were performed under the same
conditions and included the following: (i) substitution of the primary antibody with preimmune rabbit immunoglobulin G purified on a
protein A column (Pierce); (ii) omission of either the primary or secondary antibody to check for endogenous biotin and peroxidase
activity, as well as nonspecific binding of the secondary antibody; and (iii) preincubation of the primary antibody with an excess of the
immunizing peptide (4, 13).
Electron Microscopy. Mouse lungs were inflationfixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), for
morphological analyses, or with 3% paraformaldehyde0.1% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4), for immunogold
labeling. Subsequent processing, embedding, sectioning, and labeling procedures were carried out as previously described (15). Sections
were examined and photographed at 60 kV in a Philips CM10 TEM.
Wet-to-Dry Weight Ratios. Wettodry weight ratios were determined for lung tissue excised from Aqp5+/+ and Aqp5−/− mice (n = 8 each
group) as described (4).
Gas Exchange. Lung CO2 exchange was analyzed in anesthetized, mechanically ventilated Aqp5+/+ and Aqp5−/− mice (n = 6 each group)
as described (16). Mice were first ventilated with 95% O2/5% CO2 for 10 min, and two 40μl arterial blood samples were taken via a
carotid catheter to establish a baseline. Mice were then ventilated with 100% O2, and arterial blood samples were taken at 30 s, 3 min, 6
min, and 9 min under this condition. Arterial pCO2, pO2, and pH were analyzed by using a Chiron (Norwood, MA) blood gas analyzer
(model 384).
Resistance and Compliance Measurements. Pulmonary responsiveness to bronchoconstrictor agents was determined by measuring airway
pressure and flow in anesthetized, ventilated Aqp5+/+ and Aqp5−/− mice (n = 6 each group) according to a published method (17). Briefly,
anesthetized mice were tracheostomized by using a custom built cannula with ports for inspiration and expiration, and for monitoring
airway pressure and airway flow. The femoral artery and vein were cannulated for continuous monitoring of blood pressure and the i.v.
administration of drugs. Ventilation and data collection and analysis were accomplished by using a custom written software program
(Mouse Reactivity System, U.S. Environmental Protection Agency, Research Triangle Park, NC), which uses flow and pressure signals to
calculate total lung resistance (R T) and dynamic compliance (Cdyn). In addition, the airway pressuretime index (APTI) was calculated
by integrating the change in peak airway pressure for the 2min period after administration of each challenge dose, as previously
described (18). Mice were ventilated at a rate of 150 breaths per minute and a tidal volume of ≈200 μl. Values from each breathing cycle
were averaged over 2s intervals and saved to a data file. After establishing a baseline, mice were challenged with increasing doses of
Ach administered i.v. via a jugular catheter (1–1,000 ng/g body weight, delivered in a 10 μl bolus of saline). Four to eight minutes were
allowed between doses to permit a return to baseline values.
Whole Animal Barometric Plethysmography. Airway responsiveness to methacholine was determined in awake, unrestrained Aqp5+/+ and
Aqp5−/− mice (n = 6 each group) by using barometric plethysmography to measure enhanced pause (Penh), a unitless measure that has
been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine (19). Mice were
equilibrated in the plethysmography chamber for 10 min before challenge. By using a previously reported protocol (20), mice were
challenged with increasing doses of methacholine (2.5 mg/ml to 80 mg/ml) after baseline Penh was first established with aerosolized PBS.
Each dose was delivered over 1 min, and Penh was recorded continuously for 4 min afterward. Data for each mouse were analyzed and
plotted by using GraphPad PRISM software.
Tracheal Smooth Muscle Contraction. Isometric force measurements of tracheal smooth muscle contractility were determined in isolated
tracheal ring preparations from Aqp5+/+ and Aqp5−/− mice (n = 6 each group) as described (21). Cumulative concentration force
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relationships to Ach (10−8–10−4 M), and relaxation to isoproterenol (10−9–10−5 M), after a precontraction with 10−5 M Ach. Epithelial
dependent relaxation to substance P (10−9 M) or ATP (10−5 M) also were assessed.
Surfactant Protein B (SP-B) ELISA. SPB concentrations were determined from bronchoalveolar lavage or total lung homogenates from
Aqp5+/+ and Aqp5−/− mice (n = 6 each group) as described (22). SPB concentration was expressed as ng/ml of bronchoalveolar lavage
fluid and as ng SPB/mg protein. Values represent the mean value ± SE.

RESULTS
AQP5 Expression in Mouse Lung. By using immunohistochemical staining and light microscopy, AQP5 expression was previously reported in
alveolar Type I cells of the mouse lung (2), and in rat distal lung, perihilar region of the conducting airway, and nasopharynx (1, 3). In
humans, in situ hybridization and immunofluorescence were previously used to detect AQP5 expression in the apical membrane of
columnar cells of the superficial epithelium and submucosal gland acinar cells of nose and bronchial epithelia, and alveolar Type I cells
(23). Our data show that, in addition to alveolar Type I cell expression, immunohistochemical staining of lung sections from Aqp5+/+ mice
showed AQP5 immunoreactivity in epithelial cells of the trachea, main stem bronchi, and extrapulmonary lobar bronchioles, but not in the
bronchiolar epithelium of the more distal, intrapulmonary bronchioles (Fig. 1). In the trachea, immunopositive staining for AQP5 was
detected at the apical, basal, and basallateral surfaces of both secretory and ciliated epithelial cells (Fig. 1 A and B). In the main stem
bronchi, immunopositive staining was detected in cells located along the basal aspect of the bronchial epithelium, as well as along the
luminal surface in association with ciliated cells (Fig. 1 C and D). In the perihilar region of the lobar bronchioles, immunopositive
staining was restricted to cells located along the basal aspect of the epithelium (Fig. 1 E and F). Although no immunostaining was
detected in the intrapulmonary bronchioles, staining was detected along the apical, or luminal, surface of the alveolar epithelium (Fig. 1 G
and H). No immunoreactivity was observed in wildtype sections incubated with primary antibody preabsorbed with the immunizing
peptide, with preimmune serum, or with secondary antibody only controls (4). Likewise, no immunoreactivity was seen in lung sections
from Aqp5−/− mice reacted with the AQP5 antibody (data not shown).

Figure 1
Immunohistochemical localization of AQP5 in mouse airway epithelium. AQP5 expression (black reaction product) was
observed in epithelial cells of the trachea (A and B), of the right and left main stem bronchi (illustrated here, where these
structures ...

Immunogold labeling of thin sections of the distal lung with antiAQP5 antibodies revealed expression of AQP5 in alveolar type I (Fig. 2
A and B) and alveolar type II cells (Fig. 2 D and E). In type I cells, gold particles were associated with both the apical and basal cell
membranes. In type II cells, labeling of the microvilli on the apical cell membrane was most prominent. No immunospecific staining was
observed in lungs from Aqp5−/− mice (Fig. 2C).

Figure 2
Immunogold localization of AQP5 in the distal mouse lung. Thin sections of LR Gold embedded lung tissue from
Aqp5 +/+ and Aqp5 −/− mice were incubated with antiAQP5 antibody (diluted 1:30) overnight at 4°C. Bound ...

Wet-to-Dry Weight. In addition to microscopic evaluation, wettodry weight ratios were used to assess potential pulmonary edema and/or
fluid imbalance in lungs from Aqp5 null mice (data not shown). No significant difference was observed between the two genotypes,
suggesting that, under normal physiological conditions, AQP5 deficiency does not cause pulmonary edema.
Gas Exchange. Because AQP5 is expressed in the alveolar epithelium at the site of gas exchange, Aqp5+/+ and Aqp5−/− mice were
analyzed for the ability to transport gases via arterial blood exchange. Arterial blood O2, CO2, and pH were assessed under conditions of
95% O2/5% CO2, and at 30 s, 3 min, 6 min, and 9 min after a switch to 100% O2. No significant differences were observed between the
two genotypes (data not shown), suggesting that, under normal conditions, AQP5 deficiency does not result in an altered ability to
effectively exchange gases.

Airway Responsiveness. AQP5 expression in the conducting airways suggests a role for AQP5 in regulating pulmonary mechanics. Airway
reactivity was evaluated by measuring total lung resistance (R T) and dynamic compliance (Cdyn), as well as the APTI in anesthetized,
ventilated mice (Fig. 3 A–C). Aqp5−/− mice were found to be hyperreactive to intravenously administered ACh (Fig. 3 A–C) as compared
with wildtype littermates. Although there were no differences in the baseline measurements of R T and Cdyn between the two groups of
animals, the magnitude of the responses of both variables to increasing doses of ACh was increased in Aqp5 −/− mice compared with
Aqp5+/+ mice (P < 0.05). Furthermore, the APTI response to ACh, which is a measure of not only the peak magnitude but also the
duration of the constrictor response, was markedly increased in the Aqp5−/− mice.

Figure 3
Airway responsiveness of Aqp5 +/+ and Aqp5 −/− mice to i.v. bronchoconstricton. Total pulmonary resistance (R T) (A and D),
dynamic compliance (Cdyn ) (B and E), and airway pressure time index (APTI) (C and F) were measured ...

Whole body barometric plethysmography was used to determine whether hyperreactivity to bronchoconstriction could be induced via
inhalation of methacholine in awake, unrestrained, spontaneously breathing Aqp5 null mice. In this method, the enhanced pause (Penh)
was used as a measure of bronchoconstriction (see Methods). Consistent with the resistance and compliance results compiled by using
ACh as an agonist, Aqp5−/− mice were hyperreactive to bronchoconstriction by inhaled methacholine in a dosagedependent fashion (Fig.
4). Thus, AQP5 deficiency results in airway hyperreactivity to bronchoconstriction with cholinergic stimulation, independent of the route
of administration.

Figure 4
Airway responsiveness of Aqp5 +/+ and Aqp5 −/− mice to bronchoconstriction by inhaled methacholine. Penh was used as
a measure of bronchoconstriction in whole body plethysmography of awake, unrestrained mice in response to ...

Isometric Force Measurements of Tracheal Smooth Muscle. Although AQP5 expression is restricted to epithelial cells in the lung, we wanted to
rule out whether the effect of cholinergic stimulation on bronchoconstriction in the absence of AQP5 expression was mediated by a
difference in tracheal smooth muscle contractility. Isometric force measurements were analyzed by using isolated tracheal rings from
Aqp5+/+ and Aqp5−/− mice. No significant difference in AChinduced contractility (Fig. 5A) or isoproterenolinduced relaxation (after
AChinduced contraction; Fig. 5B) was observed between the tracheas from Aqp5+/+ or Aqp5−/− mice, suggesting that tracheal smooth
muscle contractility was not affected by AQP5 deficiency. Epithelialdependent relaxation to SP or ATP also was not affected (data not
shown).

Figure 5
Isometric force measurements for isolated tracheal rings from Aqp5 +/+ and Aqp5 −/− mice. Tracheal smooth muscle (A)
contraction to ACh, expressed as milliNewtons (mN) and (B) relaxation to isoproterenol are expressed as ...

Surfactant Protein-B (SP-B). SPB is a 79aa polypeptide expressed in alveolar type II cells that interacts with phospholipids to enhance the
surface tension of the alveolus in the lung (24). Deficiency in SPB has been shown to affect lung function, and results in reduced lung
compliance (25). SPB concentrations were analyzed from total lung homogenates and bronchoalveolar lavages from Aqp5+/+ and Aqp5−/−
mice. No significant differences were observed in SPB concentrations obtained from lung homogenates (Aqp5+/+ : 15.4 ± 1.46 ng SP
B/mg protein; Aqp5−/− : 14.6 ± 1.42 ng SPB/mg protein) or from lung lavages (Aqp5+/+ : 262 ± 25.7 ng SPB/ml lavage fluid; Aqp5−/− : 264
± 25.01 ng SPB/ml lavage fluid), suggesting that AQP5 deficiency did not result in altered SPB concentration.

DISCUSSION
The role of AQP5 in the regulation of lung fluid homeostasis and its potential contribution to lung function is largely unknown. In this
study, we examined the expression pattern of AQP5 in mouse lung, and analyzed parameters of lung function in Aqp5−/− mice. The results
presented here implicate a novel physiological role for AQP5 in cholinergicstimulated bronchoconstriction.
Immunohistochemical analyses showed that AQP5 expression in mouse lung was not limited to type I cells, but was also detected in
alveolar type II cells. Alveolar type II cells also express the epithelial sodium channel (ENaC), important in the transport of sodium
across the alveolar epithelium (26, 27). Because water movement through AQPs is driven by osmotic gradients that are generated by
sodium gradients, the coexpression of AQP5 and ENaC in alveolar type II cells may reflect coregulation of sodium and water transport in
the alveolar region.
Physiological examination of Aqp5−/− mice by using resistance and compliance measurements and barometric whole body
plethysmography showed that Aqp5−/− mice are hyperresponsive to bronchoconstriction by cholinergic stimulation. Our data suggest that
the observed altered reactivity is not due to altered SPB concentration. Thus, the mechanism of AQP5mediated responsiveness is not
likely to result in changes in surfactantcontrolled surface tension. Other parameters of normal lung function were not affected by AQP5
deficiency. The absence of AQP5 expression did not affect gas exchange nor did it result in pulmonary edema under normal physiological
conditions.
Identification of AQP5 expression in bronchial epithelial cells strongly implicates AQP5 as the previously described, but unidentified
mercurysensitive water channel responsible for mediating osmotically driven transcellular water flow and airway surface liquid
composition (28, 29). It has been shown that a local increase in the osmolarity of the airway surface liquid as a result of respiratory water
loss or inhalation of hypertonic saline induces bronchoconstriction in asthmatic patients (30, 31). Because bronchial epithelium has both
metabolic and secretory functions that mediate both the release of bronchodilators and removal of bronchoconstricting agents (32–34), it is
possible that the absence of AQP5 at the luminal surface of tracheal and bronchial epithelial cells leads to altered extracellular ionic
composition that could affect the release and/or clearance of bronchoreactive substances, resulting in rapid airway responses. The lack
of statistically significant alterations in smooth muscle contractility of trachea rings from Aqp5+/+ and Aqp5−/− mice may be due to the
fact that the immersion of the tracheal rings in a wellstirred PBS bath prevents changes in the local extracellular space. Alternatively, an
AQP5sensitive neural signaling pathway between the epithelium and smooth muscle may be disrupted in isolated tracheal ring
preparations. Future studies by using methods that do not disrupt the integrity of the tracheal smooth muscle microenvironment will be
needed to fully elucidate the mechanism responsible for the observed hyperreactivity.
Although our data clearly demonstrate a role for AQP5 in cholinergicstimulated bronchoconstriction in mice, a “direct” role for AQP5 in
this process has not yet been elucidated. Our data do not exclude the possibility that AQP5 ablation results in the aberrant expression of
other developmentally regulated or physiologically relevant genes whose function may provide a direct mechanism for the enhanced
bronchoresponsivenss that we observe in the Aqp5 knockout mice. Additional analyses will be required to completely dissect the pathways
involved in this AQP5dependent response.
Sensitivity of bronchial airway smooth muscle to constriction by muscarinic agonists such as Ach or methacholine characterize both
asthma and chronic obstructive pulmonary disease (COPD) in humans (33), pulmonary disorders that often are treated clinically with
anticholinergic therapy (35, 36). Although the mechanism of its involvement is not known, these results indicate AQP5 involvement in a
novel mechanism of bronchoconstriction.
Several genetic linkage studies have been conducted in both humans and mice to map the trait of airway hyperresponsiveness in asthma
susceptibility. Of relevance to this report is a mouse quantitative trait locus (QTL) genetic mapping study performed by De Sanctis and
colleagues (9). Airway hyperresponsiveness was mapped to mouse chromosome 15 (9) in the same region as the Aqp5 gene locus (12).
Two studies have mapped major asthmasusceptibility loci on human chromosome 12q (10, 11), the chromosomal location of human Aqp5
gene (12). Human chromosome 12q and mouse chromosome 15 are syntenic within this region, which contains an aquaporin gene cluster
(12, 13). None of the above linkage reports identify Aqp5 as a candidate gene locus for asthma or bronchial hyperreactivity.
To our knowledge, there have been no previous reports showing a physiological role for AQP5 in modulating airway responsiveness and
bronchoconstriction. The combined evidence presented by AQP5 lung expression patterns, physiological response to cholinergic challenge,
and the colocalization of the Aqp5 gene with chromosomal regions associated with airway hyperresponsive QTLs implicate this gene as a
candidate for susceptibility to bronchial hyperreactivity and asthma.
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